MX387295B - Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos. - Google Patents

Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos.

Info

Publication number
MX387295B
MX387295B MX2017012616A MX2017012616A MX387295B MX 387295 B MX387295 B MX 387295B MX 2017012616 A MX2017012616 A MX 2017012616A MX 2017012616 A MX2017012616 A MX 2017012616A MX 387295 B MX387295 B MX 387295B
Authority
MX
Mexico
Prior art keywords
interleukin
antibodies
methods
mutate
assays
Prior art date
Application number
MX2017012616A
Other languages
English (en)
Spanish (es)
Other versions
MX2017012616A (es
Inventor
Benjamin P Kemp
Catherine L Overed-Sayer
David C Lowe
David G Rees
Elizabeth H England
Emma S Cohen
Ian C Scott
Katherine A Vousden
Kirsty Houslay
Martin D Strain
Matthew Sleeman
Robin Butler
Sara Carmen
Tomas M Mustelin
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2017012616A publication Critical patent/MX2017012616A/es
Publication of MX387295B publication Critical patent/MX387295B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
MX2017012616A 2015-03-31 2016-03-30 Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos. MX387295B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562140913P 2015-03-31 2015-03-31
PCT/EP2016/056973 WO2016156440A1 (en) 2015-03-31 2016-03-30 A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same

Publications (2)

Publication Number Publication Date
MX2017012616A MX2017012616A (es) 2018-04-10
MX387295B true MX387295B (es) 2025-03-18

Family

ID=55640748

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012616A MX387295B (es) 2015-03-31 2016-03-30 Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos.

Country Status (29)

Country Link
US (3) US10668150B2 (enExample)
EP (3) EP3277717B1 (enExample)
JP (3) JP6862351B2 (enExample)
KR (1) KR102261618B1 (enExample)
CN (1) CN108064236B (enExample)
AU (3) AU2016239331C1 (enExample)
CA (1) CA2982400C (enExample)
CL (2) CL2017002433A1 (enExample)
CO (1) CO2017010753A2 (enExample)
CY (1) CY1123925T1 (enExample)
DK (1) DK3277717T3 (enExample)
ES (1) ES2886114T3 (enExample)
HR (1) HRP20210096T1 (enExample)
HU (1) HUE053097T2 (enExample)
IL (2) IL254551A0 (enExample)
LT (1) LT3277717T (enExample)
MX (1) MX387295B (enExample)
MY (1) MY190209A (enExample)
NZ (1) NZ736026A (enExample)
PL (1) PL3277717T3 (enExample)
PT (1) PT3277717T (enExample)
RS (1) RS61438B1 (enExample)
RU (1) RU2736299C2 (enExample)
SG (1) SG11201707593UA (enExample)
SI (1) SI3277717T1 (enExample)
SM (1) SMT202100086T1 (enExample)
TW (1) TWI721973B (enExample)
WO (1) WO2016156440A1 (enExample)
ZA (1) ZA201707355B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9758578B2 (en) 2013-12-26 2017-09-12 Mitsubishi Tanabe Pharma Corporation Human anti-IL-33 neutralizing monoclonal antibody
EP3218515B1 (en) 2014-11-10 2023-04-26 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for il-33-mediated disorders
CA2960297A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
MY190209A (en) * 2015-03-31 2022-04-05 Medimmune Ltd A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
PE20181952A1 (es) 2016-04-27 2018-12-17 Pfizer Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos
JOP20190093A1 (ar) 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
PL3558369T3 (pl) * 2016-12-21 2025-06-23 Cephalon Llc Przeciwciała specyficznie wiążące się z ludzką il-15 i ich zastosowania
MX2019012171A (es) 2017-04-13 2019-11-25 Regeneron Pharma Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1.
JP7657440B2 (ja) 2017-06-12 2025-04-07 ブルーフィン バイオメディシン， インコーポレイテッド 抗－ｉｌ１ｒａｐ抗体および抗体薬物コンジュゲート
CN115920032A (zh) 2017-08-31 2023-04-07 田边三菱制药株式会社 含有il-33拮抗剂的子宫内膜异位症治疗剂
CN107973849B (zh) * 2017-11-30 2020-07-28 畜科生物工程有限公司 一种用于增强猪疫苗免疫效果的蛋白质及其应用
WO2019183375A1 (en) * 2018-03-22 2019-09-26 Eureka Therapeutics, Inc. Antibody agents specifically recognizing monocarboxylate transporter 4 and uses thereof
IL307286B1 (en) 2018-04-11 2025-11-01 Regeneron Pharma Methods and compositions for quantifying il-33
WO2020054871A1 (ja) * 2018-09-14 2020-03-19 田辺三菱製薬株式会社 ヒト抗ｉｌ－３３モノクローナル抗体含有医薬用組成物
CN111434687B (zh) * 2019-01-15 2022-03-11 南京赛新生物科技有限公司 一种抗体及其应用
CN111434680B (zh) * 2019-01-15 2021-11-23 南京赛新生物科技有限公司 一种与il33相关疾病的抗原表位肽及其应用
US20220272953A1 (en) * 2019-07-29 2022-09-01 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric il33
CN110567861B (zh) * 2019-09-09 2021-12-21 浙江普罗亭健康科技有限公司 基于质谱流式检测技术筛查具有免疫原性抗原肽的试剂盒及检测方法
WO2021089563A1 (en) 2019-11-04 2021-05-14 Medimmune Limited Methods of using il-33 antagonists
EP4055044A1 (en) 2019-11-04 2022-09-14 MedImmune Limited Anti il-33 therapeutic agent for treating renal disorders
CN115315527A (zh) * 2020-03-13 2022-11-08 免疫医疗有限公司 用于治疗il33中存在风险等位基因的受试者的治疗方法
CA3174680A1 (en) 2020-03-13 2021-09-16 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2021204707A1 (en) 2020-04-06 2021-10-14 Medimmune Limited Treating acute respiratory distress syndrome with il-33 axis binding antagonists
BR112022022620A2 (pt) * 2020-05-11 2022-12-20 Medimmune Ltd Formulações de anticorpos anti-il-33
IL298075A (en) * 2020-05-12 2023-01-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd St2 antigen binding protein
CN111378037B (zh) * 2020-06-01 2020-09-01 南京诺艾新生物技术有限公司 一种抗hIL-33人源化单抗及其应用
EP4295154A1 (en) 2021-02-18 2023-12-27 F. Hoffmann-La Roche AG Method for resolving complex, multistep antibody interactions
CN113234157B (zh) * 2021-07-09 2021-09-21 上海普铭生物科技有限公司 亲和力成熟的人源化抗人il-33单克隆抗体及其应用
DK4244252T3 (da) * 2021-08-27 2024-09-02 Medimmune Ltd Behandling af kronisk obstruktiv lungesygdom med et anti-interleukin-33-antistof
WO2023086807A1 (en) * 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
WO2024038187A1 (en) 2022-08-19 2024-02-22 Medimmune Limited Assay for detection of il-33
EP4573121A1 (en) 2022-08-19 2025-06-25 MedImmune Limited Method of selecting patients for treatment with an il-33 axis antagonist
WO2024038186A1 (en) 2022-08-19 2024-02-22 Medimmune Limited Treatment of acute respiratory failure
TW202423972A (zh) 2022-08-26 2024-06-16 英商梅迪繆思有限公司 使用抗介白素－３３抗體的氣喘治療
KR20250168673A (ko) 2023-04-12 2025-12-02 아스트라제네카 아베 Steap2-표적화 화합물 및 이의 용도
AR134489A1 (es) * 2023-11-27 2026-01-21 Glaxosmithkline Ip Dev Ltd Proteinas de unión a antígeno
WO2025120567A1 (en) 2023-12-07 2025-06-12 Medimmune Limited Method of treatment of asthma
WO2025210099A1 (en) 2024-04-04 2025-10-09 Medimmune Limited Method of treatment and selecting a subject
WO2025242618A1 (en) 2024-05-20 2025-11-27 Medimmune Limited Bronchiectasis treatment
WO2025242619A1 (en) 2024-05-20 2025-11-27 Medimmune Limited Treatment for mucus plugging
WO2025252012A1 (en) * 2024-06-03 2025-12-11 Fbd Biologics Limited Engineered il-7 variants and methods of use thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
EP0428534B1 (en) 1988-06-14 1995-03-29 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5136964A (en) 1989-01-19 1992-08-11 Arnold J. Cook Warning device for windsurfing craft
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
EP0521985B1 (en) 1990-03-20 1997-09-24 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
DE69130709T3 (de) 1990-10-05 2005-12-22 Celldex Therapeutics, Inc. Gezielte immunostimulierung mit bispezifischen stoffen
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
ES2178635T3 (es) 1990-11-09 2003-01-01 Stephen D Gillies Inmunoconjugados de citoquinas.
DE69214709T2 (de) 1991-04-26 1997-02-20 Surface Active Ltd Neue Antikörper und Verfahren zu ihrer Verwendung
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
EP0627940B1 (en) 1992-03-05 2003-05-07 Board of Regents, The University of Texas System Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
WO2001002588A2 (en) 1999-07-02 2001-01-11 Morphosys Ag Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
BRPI0108923B8 (pt) 2000-03-03 2021-05-25 Cambridge Antibody Tech Limited elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina
JP4368196B2 (ja) 2000-11-17 2009-11-18 ユニバーシティー オブ ロチェスター 真核細胞において免疫グロブリン分子を製造および同定するインビトロにおける方法
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CN1305905C (zh) 2002-03-22 2007-03-21 Aprogen株式会社 人源化抗体及其制备方法
NZ549040A (en) * 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
KR101544108B1 (ko) 2006-09-08 2015-08-13 애브비 바하마스 리미티드 인터루킨-13 결합 단백질
WO2008137552A2 (en) 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof
EP2069784A4 (en) * 2007-05-18 2009-11-18 Medimmune Llc IL-33 IN INFLAMMATORY DISEASE
WO2009055074A2 (en) 2007-10-25 2009-04-30 Wyeth Erbb2 binding proteins and use thereof
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
JP6013915B2 (ja) * 2010-11-17 2016-10-25 中外製薬株式会社 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
MY190209A (en) * 2015-03-31 2022-04-05 Medimmune Ltd A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same

Also Published As

Publication number Publication date
US11738081B2 (en) 2023-08-29
MY190209A (en) 2022-04-05
AU2019250213A1 (en) 2019-11-07
EP4374916A2 (en) 2024-05-29
US20180207265A1 (en) 2018-07-26
JP2018516853A (ja) 2018-06-28
AU2019250213B2 (en) 2021-12-02
JP6862351B2 (ja) 2021-04-21
AU2016239331B2 (en) 2019-07-25
HK1250728A1 (zh) 2019-01-11
KR20170132811A (ko) 2017-12-04
CN108064236B (zh) 2021-12-10
PT3277717T (pt) 2021-02-01
US20240016929A1 (en) 2024-01-18
KR102261618B1 (ko) 2021-06-04
CO2017010753A2 (es) 2018-03-20
DK3277717T3 (da) 2021-02-01
SI3277717T1 (sl) 2021-03-31
RS61438B1 (sr) 2021-03-31
EP4374916A3 (en) 2024-08-28
CL2020002269A1 (es) 2021-01-22
RU2017134909A (ru) 2019-03-28
HUE053097T2 (hu) 2021-06-28
CL2017002433A1 (es) 2018-05-04
AU2016239331C1 (en) 2020-01-30
LT3277717T (lt) 2021-08-10
US20200353078A1 (en) 2020-11-12
AU2021257881A1 (en) 2021-11-18
US10668150B2 (en) 2020-06-02
EP3277717B1 (en) 2020-11-18
JP2024001166A (ja) 2024-01-09
CA2982400A1 (en) 2016-10-06
TWI721973B (zh) 2021-03-21
IL254551A0 (en) 2017-11-30
HRP20210096T1 (hr) 2021-03-05
MX2017012616A (es) 2018-04-10
AU2021257881B2 (en) 2022-02-17
BR112017020955A2 (pt) 2018-07-10
WO2016156440A1 (en) 2016-10-06
PL3277717T3 (pl) 2021-05-31
IL280045B (en) 2021-09-30
CN108064236A (zh) 2018-05-22
JP2021038226A (ja) 2021-03-11
SG11201707593UA (en) 2017-10-30
ZA201707355B (en) 2022-06-29
NZ736026A (en) 2023-02-24
SMT202100086T1 (it) 2021-03-15
ES2886114T3 (es) 2021-12-16
CA2982400C (en) 2023-10-24
RU2736299C2 (ru) 2020-11-13
TW201704259A (zh) 2017-02-01
IL280045A (en) 2021-03-01
EP3277717A1 (en) 2018-02-07
EP3733701A1 (en) 2020-11-04
CY1123925T1 (el) 2022-05-27
RU2017134909A3 (enExample) 2019-12-23
AU2016239331A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
MX387295B (es) Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos.
BR112019012342A2 (pt) anticorpos il-11
CR20190271A (es) Anticuerpos antitau y métodos de uso
MX2024011869A (es) Anticuerpos anti-tau y metodos de uso
MX2017015464A (es) Anticuerpos anti-tau y metodos de uso.
BR112019012343A2 (pt) anticorpos il-11ra
MX2020000960A (es) Anticuerpos anti-tigit.
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX385915B (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos
CL2017002237A1 (es) Proteína de unión de il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
EA202092435A2 (ru) Моноклональные антитела против bcma
MX375032B (es) Proteínas de unión y métodos para utilizarlas.
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
ZA201807920B (en) Anti¿gitr antibodies and uses thereof
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
MX2022002954A (es) Anticuerpos anti-htra1 y metodos de uso de los mismos.
CR20200404A (es) Anticuerpos anti-klk5 y métodos de uso